Central labs receive 300 cough syrup samples

NEW DELHI : Government laboratories have received around 300 cough syrup samples for quality testing after the embarrassment of toxic syrups causing deaths abroad.

Indian-made cough syrups have been linked to the death of dozens of children in Uzbekistan and Gambia, prompting the government to tighten the export policy for cough syrups. It is now mandatory to test before supplying to other countries.

As of 4 July, Central labs in Chennai, Mumbai, Kolkata, Ghaziabad (UP), Chandigarh, Gujarat and Jammu had received samples.

On the other hand, government labs in Karnataka, Kerala, Bhopal, Maharashtra, and Uttarakhand, Hyderabad and Guwahati are yet to receive any. The drug regulator has issued an alert to all manufacturers not to over-burden one particular lab for testing.

India, the largest provider of generic drugs globally, exported cough syrups worth $17.6 billion in 2022-23 as against $17 billion in 2021-22. India’s pharma export body Pharmexcil has over 2,000 manufacturers registered with it, and most are manufacturing cough syrups. Queries sent to the health ministry spokesperson did not elicit any response.

Related Posts

Commissioner FDA reviews enforcement measures

Srinagar: Commissioner, Food & Drugs Administration (FDA), Jammu & Kashmir, Khalid Jahangir on Thursday held an introductory meeting with senior officers and field functionaries of Drug and Food Wing of the…

Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

Karnataka High Court Ashwagandha ruling offers interim relief to supplement makers challenging the FSSAI advisory on Ashwagandha extracts. The Karnataka High Court has stayed an advisory issued by the Food…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Commissioner FDA reviews enforcement measures

Commissioner FDA reviews enforcement measures

Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

Roche Pharma launches Tecentriq® SC, India’s first subcutaneous immunotherapy for lung cancer

Roche Pharma launches Tecentriq® SC, India’s first subcutaneous immunotherapy for lung cancer

CDSCO tighten drug quality oversight as substandard and spurious medicine cases rise in five years

CDSCO tighten drug quality oversight as substandard and spurious medicine cases rise in five years

Piramal Pharma Gets 3 USFDA Observations at US Facility

Piramal Pharma Gets 3 USFDA Observations at US Facility

Eli Lilly pauses Indian obesity awareness campaign after regulatory notices

Eli Lilly pauses Indian obesity awareness campaign after regulatory notices